Immodulon Therapeutics Ltd.
🇬🇧United Kingdom
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT03711188
- Locations
- 🇬🇧
The Christie Hospital, Manchester, United Kingdom
🇬🇧St George's University Hospitals NHS Foundation Trust, London, United Kingdom
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
Phase 1
Terminated
- Conditions
- Metastatic Cancer
- Interventions
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 2
- Registration Number
- NCT03009058
- Locations
- 🇫🇷
Centre Léon Bérard, Dpt Medecine & INSERM, Lyon, France
🇫🇷Gustave Roussy Cancer Center, Villejuif, France
🇬🇧St George's University of London, Institute of Infection and Immunity, London, United Kingdom
A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
Phase 1
Terminated
- Conditions
- Malignant Melanoma
- Interventions
- Biological: IMM-101
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT01559818
- Locations
- 🇬🇧
St Georges University of London, London, United Kingdom
A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer
Phase 2
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Radiation: SBRT
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT01539824
- Locations
- 🇬🇧
HCA International, The Sarah Cannon Research Institute, London, United Kingdom
🇬🇧The London Clinic, London, United Kingdom
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
Phase 1
Completed
- Conditions
- Melanoma
- Interventions
- Biological: Heat killed whole cell M. obuense (IMM-101) 0.1 mgBiological: Heat-killed whole cell M.obuense (IMM-101) 0.5 mgBiological: Heat killed whole cell M.obuense (IMM-101) 1.0 mg
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 19
- Registration Number
- NCT01308762
- Locations
- 🇬🇧
HCA Clinical Trials Unit, 79 Harley Street,, London, United Kingdom
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Phase 2
Completed
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- Biological: IMM-101
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 110
- Registration Number
- NCT01303172
- Locations
- 🇮🇪
St Vicents University Hospital, Dublin, Ireland
🇪🇸Hospital General de Alicante, Alicante, Spain
🇪🇸Hospital Miguel Servet, Zaragoza, Spain
© Copyright 2025. All Rights Reserved by MedPath